
IRIDEX Corporation: stock overview
Price
$0.69
November 13, 2026Market cap $12M
What Ploutos Investor adds for IRIDEX
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 26% since Aug 18, 2026, when the 10-Q these figures come from was filed ($0.93 then, $0.69 on Nov 13, 2026). The figures date from before that move.10-Q
In short
IRIDEX had revenue of $52M over the last 12 months and a net loss of $3.5M. Revenue grew by 7.7% a year on average over the last 5 years. It holds more cash than debt, by $885.0K. It pays no dividend.
From its SEC filings (latest fiscal year to January 3, 2026) and the price of November 13, 2026.
Its SEC filings- Market cap
- $12M
- 17.31M shares
- P/E
- –
- Revenue, 12 months
- $52M
- +7.7% a year over 5 years
- Net margin
- -6.9%
- FY2025: -8.4%, above 37% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+0.8% a year over 2 years
Fiscal years in figures
IRIX's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $28M
- $12M
- Enterprise value
- $11M
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 0.2
- P/B 3-year median: 4.8
- 3.3
- FCF yield 3-year median: -15.0%
- –
- Earnings yield 3-year median: -22.2%
- –
Profitability
- Gross margin
- 35.9%
- Operating margin
- -5.4%
- Net margin 3-year median: -18.3%
- -6.9%
- ROIC
- -24.7%
- ROIC, 5-year average
- -60.7%
- ROE
- -73.8%
Growth
- Revenue, yearly change
- +8.2%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +7.7%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $4.7M
- Total debt
- $4.0M
- Of which operating leases
- $218.0K
- Net cash
- $885.0K
- Net debt / EBITDA
- –
- Interest cover
- -47.9x
- Current ratio
- 1.82
Balance sheet of July 4, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +3.1%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).
Gross margin
36.5%
Above 18% of the 161 companies in its industry, and 50% of all.
Operating margin
-4.9%
Above 41% of the 186 companies in its industry, and 25% of all.
Net margin
-8.4%
Above 37% of the 189 companies in its industry, and 20% of all.
ROA
-15.2%
Above 24% of the 190 companies in its industry, and 11% of all.
Revenue growth
8.2%
Above 51% of the 186 companies in its industry, and 56% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- IRIDEX CORP
- CIK
- 1006045
- Exchange
- NASDAQ
- Industry (SIC)
- 3845 · Electromedical & Electrotherapeutic Apparatus
- Fiscal year ends
- January 3
- Latest annual report
- January 3, 2026
- Reporting currency
- USD
- Shares
- 17.31M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with IRIX
- JNJJohnson & Johnson+0,00%Compare with IRIX
- ABBVAbbVie+0,00%Compare with IRIX
- UNHUnitedHealth+0,00%Compare with IRIX
- MRKMerck & Company+0,00%Compare with IRIX
- AMGNAmgen+0,00%Compare with IRIX
- TMOThermo Fisher Scientific+0,00%Compare with IRIX
- ABTAbbott Laboratories+0,00%Compare with IRIX
The full analysis
What do IRIDEX's filings show?
These are IRIDEX's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is IRIX's market cap?
IRIDEX Corporation's market cap is $12M, at a price of $0.69 on November 13, 2026 and 17.31M shares.
How much revenue does IRIX have?
IRIDEX had revenue of $52M over the last 12 months. Over the last 5 years it changed by +7.7% a year on average.
Does IRIX pay a dividend?
No. IRIDEX paid no regular dividend over the last 12 months.
Where do the figures come from?
From IRIDEX Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.